Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Esophagus-sparing VMAT/IMRT did not reduce peak dysphagia in the intention-to-treat analysis but showed a significant benefit in the per-protocol analysis.
Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders.
Monthly and quarterly fremanezumab significantly reduced the monthly average number of migraine days versus placebo regardless of country and continent (North America versus Europe) in migraine patients with documented...
Ivarmacitinib 4 mg demonstrated consistent efficacy in patients with active AS across diverse demographic and clinical subgroups.
The initial results of this trial indicate that ansofaxine at both the 80 mg/day and 160 mg/day was effective and safe in adult patients with MDD.
CKD-828 is an effective and safe option for patients with inadequate responses to S-amlodipine single-drug treatment.
Clinical and histologic full symptom relief of EoE could be maintained with BOT in a large majority of patients for up to 96 weeks, and for up to 144 weeks in patients with uninterrupted BOT therapy across all trials.
Haplo-BMT is a fair value choice for commercially insured patients with high-risk leukemia and lymphoma who require HCT.
OnabotulinumtoxinA was efficacious and well tolerated in women and in men with lower PSA levels.
Both CZP 200 mg and 400 mg Q2W demonstrated sustained, durable efficacy, with numerically higher responses for some outcomes with 400 mg Q2W.
Gefapixant 45 mg twice daily is the first treatment to show efficacy versus placebo in reducing CSUI episodes in participants with refractory or unexplained chronic cough.
Fixed-dose combination amlodipine/losartan 5/50 mg was not inferior in terms of reductions in DBP after 8 weeks of treatment and had comparable safety profile to amlodipine 10 mg in patients who did not respond to amlodipine 5...
These MCID thresholds for the OHQ, OHSA and OHSA item 1 alone, enhance the interpretability of scores and support their use in evaluating clinical benefit.
Fremanezumab demonstrated a favorable safety profile, with no safety signals.
Both lumateperone doses were well tolerated, with low EPS risk and minimal changes in weight, prolactin, and cardiometabolic or endocrine parameters.
BCG vaccine is safe and offers cross-protection against COVID-19 with potential humoral response modulation.
HLX01 plus methotrexate improved clinical outcomes compared with placebo in Chinese patients with autoimmune joint pain (autoimmune joint pain (rheumatoid arthritis)) who had inadequate responses to methotrexate.
No significant differences in OS were observed between the ER and GE arms in all patients with EGFR mutation and those with brain.
Difamilast ointment 1% demonstrated superiority to the vehicle and favorable safety in adult Japanese patients with eczema.
Ibrutinib confirms efficacy in CLL patients at an early stage with an increased risk of progression.
The 25 mg BIW etanercept dosage does not appear to be significantly more efficacious than 10 mg in Japanese patients with RA.
After prolonged follow-up of 80 months, the risk of kidney complications did not seem increased by a pre-operative radiation approach as shown in this ancillary study of the STRASS.
Early ctDNA monitoring and modeling have the potential to significantly enhance treatment personalization.
Upadacitinib 15 mg QD demonstrated sustained improvement up to 52 weeks in bDMARD-IR patients with AS.
Addition of bisoprolol to patients uncontrolled with amlodipine single-drug treatment significantly improves blood pressure control.
RT was associated with short-term perfusion defects that improved within 1 year and was not correlated with late cardiac events.
Preoperative dexamethasone reduced systemic inflammation but did not improve postoperative recovery, pain, or nausea after head and neck cancer surgery with free tissue transfer reconstruction.
There were no differences in progression-free survival between the patients with at least partial immunoglobulin recovery and the remaining population.
A single dose of MenACYW-TT was well tolerated, with a non-inferior seroresponse compared with MCV4-DT.
The primary endpoint is overall survival; secondary endpoints are progression-free survival, response rate, proportion with negative peritoneal washing cytology during chemotherapy, proportion requiring conversion surgery, and...
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
